Beyaz generic
Beyaz is a contraceptive and preventative medicine owned by Bayer Hlthcare. It was first authorized for market use on 24 September, 2010. Composed of Drospirenone; Ethinyl Estradiol; and Levomefolate Calcium, Beyaz is available in tablet form for oral consumption.
When will Beyaz generic be available?
The generic versions of Beyaz are expected to be released after 17 July, 2030. This is due to the expiration of the last patent, No. US11617751 titled 'Pharmaceutical composition containing a tetrahydrofolic acid', on that date.
Beyaz uses
Beyaz is primarily used for the prevention of pregnancy. Additionally, it serves to raise folate levels in women who choose to use an oral contraceptive as their method of contraception, thereby reducing the risk of a neural tube defect in a pregnancy. It is also prescribed for the treatment of moderate acne vulgaris in women at least 14 years old who also desire an oral contraceptive for birth control. Furthermore, Beyaz aids in the treatment of mood changes and/or anxiety as symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use it as their method of contraception.
Beyaz patent expiration
Beyaz is protected by 2 remaining drug patents out of an original total of 4. The expired patents are US7163931 and US6441168. The two still effective patents include US8617597 with a title of 'Pharmaceutical composition containing a tetrahydrofolic acid' and the last one US11617751 titled 'Pharmaceutical composition containing a tetrahydrofolic acid'. The availability of Beyaz generic versions is anticipated only after the expiry of the final patent on 17 July, 2030. Below are the details of the patent: